Tocilizumab Combined with Ruxolitinib in the Treatment of Children with Steroid Resistant Graft Versus Host Disease After Hematopoietic Stem Cell Transplantation: Report of 6 Cases

Overview

Journal Zhejiang Da Xue Xue Bao Yi Xue Ban

Specialty General Medicine

Date 2023 May 18

PMID 37202101

Authors

Jie Chen

Jingyuan Lu

Xiuli Hong

Quanyi Lu

Affiliations

Soon will be listed here.

Abstract

Six children with steroid resistant graft versus host disease (GVHD) after hematopoietic stem cell transplantation admitted in the hospital, including 4 cases of acute GVHD and 2 cases of chronic GVHD. Among the 4 acute GVHD cases, the main manifestations were large area rash and fever in 2 cases, and abdominal pain and diarrhea in 2 cases. In 2 chronic GVHD cases, one presented lichenoid dermatosis, and the other showed repeated oral ulcers with difficult mouth opening. Patients received tocilizumab (8 mg/kg per dose every 3 weeks) and ruxolitinib (5-10 mg/d, 28 d), at least 2 courses were completed. All patients had complete responses (100%), and 5 patients responded after completion of two treatment courses, with the median time of remission was 26.7 d. The median follow-up period was 11 (7-25) months, and no severe treatment-related adverse reactions were observed.

References

Westin J, Saliba R, de Lima M, Alousi A, Hosing C, Qazilbash M . Steroid-Refractory Acute GVHD: Predictors and Outcomes. Adv Hematol. 2011; 2011:601953. PMC: 3216266. DOI: 10.1155/2011/601953. View

Chen X, Das R, Komorowski R, Beres A, Hessner M, Mihara M . Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood. 2009; 114(4):891-900. PMC: 2716024. DOI: 10.1182/blood-2009-01-197178. View

Laisne L, Neven B, Dalle J, Galambrun C, Esvan M, Renard C . Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC. Pediatr Blood Cancer. 2020; 67(9):e28233. DOI: 10.1002/pbc.28233. View

Yucebay F, Matthews C, Puto M, Li J, William B, Jaglowski S . Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience. Leuk Lymphoma. 2019; 60(9):2223-2229. DOI: 10.1080/10428194.2019.1573996. View

Kennedy G, Varelias A, Vuckovic S, Le Texier L, Gartlan K, Zhang P . Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014; 15(13):1451-1459. DOI: 10.1016/S1470-2045(14)71017-4. View

MacMillan M, Weisdorf D, Wagner J, DeFor T, Burns L, Ramsay N . Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant. 2002; 8(7):387-94. DOI: 10.1053/bbmt.2002.v8.pm12171485. View

Hoda D, Pidala J, Salgado-Vila N, Kim J, Perkins J, Bookout R . Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant. 2009; 45(8):1347-51. DOI: 10.1038/bmt.2009.343. View

Tawara I, Koyama M, Liu C, Toubai T, Thomas D, Evers R . Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res. 2010; 17(1):77-88. PMC: 3058832. DOI: 10.1158/1078-0432.CCR-10-1198. View

Kim J, Sohn S, Kim D, Lee N, Suh J, Lee K . Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol. 2004; 73(1):56-61. DOI: 10.1111/j.1600-0609.2004.00247.x. View

10.

Hill L, Alousi A, Kebriaei P, Mehta R, Rezvani K, Shpall E . New and emerging therapies for acute and chronic graft host disease. Ther Adv Hematol. 2018; 9(1):21-46. PMC: 5753923. DOI: 10.1177/2040620717741860. View

11.

Benito A, Furlong T, Martin P, Anasetti C, Appelbaum F, Doney K . Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation. 2002; 72(12):1924-9. DOI: 10.1097/00007890-200112270-00010. View

12.

DSouza A, Lee S, Zhu X, Pasquini M . Current Use and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant. 2017; 23(9):1417-1421. PMC: 5565685. DOI: 10.1016/j.bbmt.2017.05.035. View

13.

Bolanos-Meade J, Jacobsohn D, Margolis J, Ogden A, Wientjes M, Byrd J . Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol. 2005; 23(12):2661-8. DOI: 10.1200/JCO.2005.06.130. View

14.

Drobyski W, Pasquini M, Kovatovic K, Palmer J, Rizzo J, Saad A . Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant. 2011; 17(12):1862-8. PMC: 3716013. DOI: 10.1016/j.bbmt.2011.07.001. View

15.

Roddy J, Haverkos B, McBride A, Leininger K, Jaglowski S, Penza S . Tocilizumab for steroid refractory acute graft-versus-host disease. Leuk Lymphoma. 2015; 57(1):81-5. PMC: 4698359. DOI: 10.3109/10428194.2015.1045896. View

16.

Kennedy G, Tey S, Buizen L, Varelias A, Gartlan K, Curley C . A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis. Blood. 2021; 137(14):1970-1979. DOI: 10.1182/blood.2020009050. View

17.

Tanaka T, Narazaki M, Kishimoto T . Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol. 2011; 52:199-219. DOI: 10.1146/annurev-pharmtox-010611-134715. View